ClinicalTrials.gg
WithdrawnNCT06875141Updated Jun 4, 2025

DM199 for Pregnancy Complications

An interventional study of DM199 in Pre-Eclampsia, sponsored by DiaMedica Therapeutics Inc. Withdrawn. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by DiaMedica Therapeutics Inc · Not applicable, Interventional, and Other

Why this study was withdrawn
This entry was unauthorized and has been withdrawn.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

This entry was submitted in error by DiaMedica Therapeutics, Inc. and was not authorized by any of the trial Investigators or study sponsor (Stellenbosch University).

The clinical trial, DM199 for Pregnancy Complications, was prospectively registered with the Pan African Clinical Trials Registry (PACTR202404895013782), in accordance with ICMJE and WHO requirements. This listing serves as the primary and authoritative registration record for this investigator-initiated study.

02

Conditions studied

  • Pre-Eclampsia

Browse trials for

03

In context

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 245 are open to participants now.

Browse Pre-Eclampsia studies →

Lead sponsor

DiaMedica Therapeutics Inc is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Please refer to the Pan African Clinical Trials Registry (PACTR202404895013782).

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Part 1

    Part 1

    Biological: DM199

Interventions

  • BiologicalDM199

    DM199 is a synthetic form of rhKLK1

06

What researchers measure

Primary outcomes

  1. Incidence of treatment adverse events

    Time frame: Until 6 weeks after the due date

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for May 2025, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 13, 2025
StartEst.
May 2025
Primary completionEst.
May 2025
CompletionEst.
May 2025
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06875141
Lead sponsor
DiaMedica Therapeutics Inc
Responsible party
Sponsor
First posted
Mar 13, 2025
Start date
May 2025 (estimated)
Primary completion
May 2025 (estimated)
Completion
May 2025 (estimated)
Last update
Jun 4, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DM199

Start the discussion